Monolax

Quick links to important sections

Monolax

Method of action: Laxative

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Monolax

Property Description
Active Ingredient Bisacodyl
Primary Forms Enteric-coated Tablet, Suppository
Pharmacological Class Stimulant Laxative / Contact Laxative
General Purpose Relief of occasional constipation
Chemical Origin Synthetic (Diphenylmethane derivative)

Monolax is a medicinal preparation classified as a laxative that is specifically formulated for the efficient relief of occasional constipation and to aid in complete bowel cleansing for medical procedures. The core identity of Monolax stems from its classification as a stimulant or contact laxative, which means it actively promotes movement within the large intestine. It is used to relieve occasional constipation and is recognized for its function in preparing the bowel for surgery or examination.

This pharmaceutical product is clinically recognized for its predictable action and is often chosen for scenarios requiring reliable overnight or rapid relief, distinguishing it from agents that require a build-up period. The drug's mechanism is distinct from osmotic agents or bulk-forming fibers, positioning it as a fast-acting tool for when more direct assistance is required to facilitate waste elimination.


What Type of Medicine is Monolax?

Monolax belongs to the stimulant laxative pharmacological class, a category recognized in pharmaceutical science. The active substance responsible for this action is Bisacodyl.

Bisacodyl is a synthetic diphenylmethane derivative that functions as a pro-drug; it remains inactive until metabolized in the colon to its potent form, Bis-(p-hydroxyphenyl)-pyridyl-2-methane. The preparation is commonly available in several dosage forms, including the enteric-coated tablet for oral intake, which prevents premature activation in the stomach, and the suppository for rectal administration. The use of the enteric coating is a differentiating factor, ensuring targeted delivery and effect in the colon.


The Essential Purpose of Stimulant Laxatives

The general purpose of Monolax is to actively encourage the process of elimination by stimulating colonic motor activity and increasing the water content of stool. This combination of increased muscle contraction and fluid secretion into the large bowel provides effective, predictable action.

The primary benefit is the restoration of comfortable and complete bowel function when a patient experiences acute, occasional constipation. This class of medicine functions to expedite intestinal transit time, ensuring the efficient passage of contents necessary for temporary relief or preparation for examinations.

Regulatory References

  1. Bisacodyl: MedlinePlus Drug Information
  2. MedlinePlus Drug Information

What side effects are possible with Monolax?

Possible Side Effects and Safety Information

The official safety profile for Monolax (Bisacodyl) is structured around frequency classifications and effects on physiological systems, as documented in government regulatory labeling. Most documented adverse reactions are categorized as Gastrointestinal Disorders.

Frequency Classification of Adverse Reactions

The following effects are classified by their documented occurrence rate, consistent with regulatory standards:

  • Common (may affect up to 1 in 10 people): Abdominal pain, abdominal cramps, diarrhoea, and nausea.
  • Uncommon (may affect up to 1 in 100 people): Dizziness, vomiting, abdominal discomfort, and haematochezia (blood in stool).
  • Rare (may affect up to 1 in 1,000 people): Syncope (fainting), severe hypersensitivity reactions (such as anaphylactic reactions and angioedema), dehydration, and colitis.

Serious Safety Characteristics

Rare, clinically significant adverse reactions officially listed include anaphylactic reactions and colitis. The regulatory label explicitly notes that fluid and electrolyte imbalance (e.g., hypokalaemia) is a serious safety concern specifically associated with the prolonged or excessive use of stimulant laxatives, not standard short-term application. Syncope and dizziness are sometimes reported as a vasovagal response linked to abdominal pain or straining during the act of elimination.

Population and Administration Safety Notes

Safety documents specify that patients with conditions involving fluid loss, such as older adults, may be particularly vulnerable to harm from dehydration. Use is generally not recommended for children under 10 years without medical supervision. To maintain the safety of the medicine, the regulatory label advises against taking enteric-coated tablets with antacids or milk, as this can prematurely dissolve the coating and lead to potential gastric irritation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory guidance explicitly mandates that patients must talk to a doctor or go to a hospital straight away if they have taken more than the recommended dose, and are instructed to take the medicine pack for identification.

Documented Overdose Manifestations

Acute overdose from high doses typically presents with severe gastrointestinal disturbances, including watery stools (diarrhoea) and abdominal cramps, resulting in a clinically significant loss of fluid and electrolytes. The potential for dehydration is a documented complication.

Chronic overdose, or laxative abuse, is associated with more severe, systemic manifestations. These include chronic diarrhoea, hypokalaemia (low potassium), secondary hyperaldosteronism, metabolic alkalosis, and potential renal tubular damage or renal calculi (kidney stones). Muscle weakness secondary to hypokalaemia is also a documented concern.

Emergency Response and Management

The supportive management officially required involves the replacement of fluids and correction of electrolyte imbalance. This treatment is considered especially important for the elderly and the young due to their higher vulnerability. If oral forms have been recently ingested, absorption may be minimized by inducing vomiting or performing gastric lavage, as no specific antidote is known. The prescribing information strictly emphasizes that the patient must seek urgent medical attention for any ingestion exceeding the labeled dosage.

Therapeutic Uses of Monolax

Main Uses of Monolax

Monolax is a medication primarily used for the management of constipation. It belongs to a class of drugs known as osmotic laxatives, which work by increasing the water content in the intestinal tract. This process softens the stool and promotes regular bowel movements.

Short-term Relief of Constipation

The primary application of Monolax is the relief of occasional constipation. By drawing fluid into the colon, it helps to facilitate the passage of dry or hard stools that may be difficult to evacuate. This action assists in restoring a more natural rhythm to the digestive system without stimulating the intestinal muscles directly.

Preparation for Medical Procedures

In certain clinical settings, Monolax may be utilized to clear the bowel in preparation for diagnostic examinations or surgical procedures. Ensuring the intestinal tract is free of waste is essential for the accuracy of imaging and the safety of abdominal interventions.

Benefits of Monolax

Predictable Action

As an osmotic agent, Monolax provides a predictable physiological response. Unlike stimulant laxatives, which can cause sudden urgency or cramping, osmotic laxatives generally work gradually, allowing for a more controlled and comfortable experience for the patient.

Consistency Improvement

One of the significant benefits of this treatment is the improvement of stool consistency. By maintaining hydration within the fecal mass, it reduces the physical strain associated with bowel movements, which can be particularly beneficial for individuals with sensitive gastrointestinal conditions.

Support for Digestive Comfort

By facilitating regular evacuation, Monolax helps alleviate the physical discomfort, bloating, and sensation of fullness often associated with irregular bowel habits. This contributes to overall gastrointestinal well-being and helps patients maintain their daily routines without the interruption of constipation-related symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Monolax (Bisacodyl) eligibility is strictly defined by regulatory documents, distinguishing between populations that are permitted to use the medicine and those who are absolutely prohibited.

Absolute Contraindications (Must Not Use)

Official labeling mandates that Monolax is contraindicated in patients with conditions such as ileus (intestinal obstruction or paralysis), intestinal obstruction, and acute abdominal conditions including appendicitis or acute inflammatory bowel diseases. Use is also strictly prohibited for individuals with severe dehydration or known hypersensitivity to Bisacodyl.

Age-Group and Conditional Eligibility

The medicine is generally allowed for use by adults and children 12 years and over. However, Monolax is not recommended for use in children under 10 years without medical advice. In cases of renal insufficiency or fluid loss, use is conditional, requiring close medical supervision if dehydration is observed. For pregnant or breastfeeding individuals, use is restricted and permitted only under the guidance of a healthcare professional due to limited controlled study data.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Monolax (Bisacodyl) is primarily characterized by required administration timing separation and potential pharmacodynamic reinforcement, rather than systemic metabolic interactions.

Timing-Dependent Physical/Chemical Interactions

Co-administration of the oral, enteric-coated tablet formulation with certain products must be avoided within a specific timeframe. Taking Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, or Milk/Dairy Products concurrently can cause the tablet's enteric coating to dissolve prematurely. This premature breakdown can alter the intended colonic delivery and may result in gastric irritation. Regulatory documents mandate that oral Bisacodyl tablets must be separated from these products by at least one hour.

Pharmacodynamic Reinforcement

Official labeling documents an additive risk when Monolax is used with other specific drug classes. The simultaneous use of Bisacodyl with Diuretics or Adreno-corticosteroids may increase the risk of hypokalaemia (low potassium) due to additive effects on electrolyte disturbance. This electrolyte imbalance is particularly relevant, as it may heighten patient sensitivity to, and potential toxicity of, co-administered Cardiac Glycosides.

Interaction Scope Summary

Classification Regulatory Status Constraint
Timing Separation Mandatory Restriction Administer oral tablets ge 1 hour apart from Antacids/Dairy.
Additive Risk Pharmacodynamic Increased risk of hypokalaemia with Diuretics/Corticosteroids.
Metabolic/CYP Not Documented No clinically significant CYP or transporter-mediated interactions listed.

Mechanism of Action

The action of Monolax is driven by its single active metabolite, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which engages two complementary and localized mechanistic domains within the colon, resulting in the physiological effect of enhanced colonic output. The overall mechanism is strictly peripheral, acting locally rather than systemically.

The first domain is the Direct Activation of Colonic Motility Pathways. BHPM acts as a direct stimulant of enteric neurons (nerve endings) in the large intestine . This initiates signaling sequences that enhance parasympathetic reflexes, increasing the frequency and force of peristalsis (High-Amplitude Propagated Contractions). This leads to a fundamental physiological effect: a decrease in colonic transit time by generating increased propulsive force.

The second domain is the Modulation of Epithelial Fluid Dynamics. BHPM focuses on the colonic lining, where it modulates epithelial fluid transport pathways . The molecule promotes active secretion (via adenylate cyclase/cAMP activation) and inhibits reabsorption (by negatively modulating water channels like Aquaporin-3). This dual action results in a core physiological change: a significant increase in the overall water content of the luminal contents, resulting in a fecal mass with elevated hydration.

Dosage and Administration Information

Monolax is used according to two administration routes: oral (as an enteric-coated 5 mg tablet) and rectal (as a 10 mg suppository or enema). The standard adult oral dose for occasional use ranges from 5 mg to 15 mg taken in a single daily dose. The rectal route typically involves a single 10 mg suppository, also administered once daily.

There are distinct schedules based on the chosen route. The oral tablet is generally intended for administration at bedtime to produce a bowel movement the following morning, leveraging its 6 to 12 hour delayed-release design. In contrast, the rectal suppository is used when a rapid effect is desired, as its action typically begins within 15 minutes to 1 hour.

Proper administration of the oral tablet requires it to be swallowed whole without crushing, chewing, or splitting. To protect the enteric coating and ensure targeted delivery, the tablet must not be taken within 1 hour of consuming antacids or any dairy products. Administration is strictly limited to short-term use for occasional needs and should not exceed 5 to 7 consecutive days.

Specific reduced dosing is defined for pediatric patients aged 6 to under 12 years, who should receive a single daily dose of 5 mg, whether by tablet or suppository. Use in children under 6 years requires the explicit guidance of a physician.

Recent Clinical Evidence

Research evidence / Overview of studies for Monolax


Studies examining outcomes related to Constipation

Research explored Monolax in the context of conditions characterized by fluctuating or episodic manifestations, such as constipation. Research has focused on understanding the patterns observed when Monolax is applied in studies examining patient-reported experiences related to bowel regularity. These clinical trials have typically been conducted during periods of increased symptom activity and studies explored how quickly changes were observed in the populations under evaluation.

The research generally focused on outcomes related to physical discomfort that were measured in the studies, specifically the ease of passing stool, and outcomes reflecting daily functioning or activity level. Data from these settings show patterns related to changes in the frequency of bowel movements compared to placebo or no treatment. Finding that the use of Monolax was associated with changes measured during the study period, particularly in the short term. The evidence primarily focuses on short-term or episodic symptom patterns.

It is important to understand that these findings describe group patterns, not personal outcomes. The specific effect for any one person may vary. The evidence contributes to understanding symptom patterns, but certainty remains low on specific outcomes.


Evidence for specific patient groups

Research has examined the use of Monolax across various adult populations, including older individuals experiencing conditions marked by functional limitations related to chronic constipation. The way Monolax was evaluated in these groups often involved observational settings evaluating daily-life functioning and how well individuals adhered to the regimen. For many laxative products, including Monolax, follow-up durations were limited, and the evidence largely describes short-term effects.

The evidence suggests patterns related to a change in the frequency of bowel movements were observed in many adult patients, but results apply only to the populations studied.


Limitations in the current research landscape

The current evidence is limited in several key areas. While studies help show what has been observed so far, the data for certain groups remain insufficient, especially for long-term use. The majority of studies were observed in highly controlled trial settings, and the results apply only to the populations studied and the specific conditions under which they were conducted. Long-term effects are not fully established regarding systemic or functional imbalance over time. Additionally, for complex cases of constipation, comparative evidence is lacking. Research is ongoing to better characterize the full scope of response.

Frequently Asked Questions (FAQ)

Common questions about Monolax (FAQ)

Q: Is Monolax a prescription drug or can you buy it over the counter?

A: According to official product information, Monolax (bisacodyl) is recognized as an Over-The-Counter (OTC) medicine. It is typically available for the temporary relief of occasional constipation and does not generally require a doctor’s prescription for use.


Q: What happens if I stop taking Monolax suddenly?

A: Since Monolax is for short-term use, stopping its use abruptly is generally the norm. However, regulatory guidance notes that prolonged or chronic use can lead to dependence, meaning the bowels may become reliant on the medication to function properly. Official guidance suggests consulting a healthcare professional is necessary to discuss cessation if the medicine has been used long-term.


Q: What types of food should I avoid while taking Monolax?

A: Official information states that the oral tablet should be separated from antacids or milk/dairy products by at least one hour. Taking the tablet with these substances can cause its protective coating to dissolve too early in the stomach, which may result in gastric irritation.


Q: Can I take my regular vitamins or supplements while on Monolax?

A: Regulatory guidance suggests that chronic use of Monolax may reduce the body’s ability to absorb certain fat-soluble vitamins (A, D, E, and K). Since herbal supplements are generally not tested for interaction in the same way, official regulatory information suggests that the use of any supplements should be reviewed by a healthcare professional.


Q: What if I forget to take Monolax one day?

A: Official guidance for short-term, as-needed medicines typically states that if a dose is missed, double dosing should be avoided. Use may be resumed as needed, according to the official administration instructions.


Q: Does Monolax affect blood pressure?

A: The drug itself is not listed as directly causing blood pressure changes. However, regulatory documents report that patients sometimes experience dizziness or syncope (fainting), which can be due to a temporary change in blood flow linked to a vasovagal response from abdominal spasms or straining.


Q: Do lifestyle changes make Monolax more effective?

A: Regulatory context often indicates that the use of stimulant laxatives, such as Monolax, is complementary to non-drug management strategies. Official guidelines on constipation care usually emphasize the importance of fluid intake and fiber consumption.


Q: What happens if Monolax doesn't seem to be working for me?

A: Official product information states that if a bowel movement does not occur after use, or if the product is needed for more than one week, the regulatory guidance is to discontinue use and seek advice from a healthcare professional.


Q: Does taking Monolax affect my ability to drive or operate machinery?

A: Official regulatory documents indicate that if a patient experiences side effects such as dizziness, syncope, or severe abdominal spasm, caution is advised when performing potentially hazardous tasks like driving or operating machinery.


Q: Does Monolax interact with herbal supplements like St. John's Wort?

A: Information on interactions with herbal and complementary medicines is not consistently available in official product information. Regulatory bodies generally note that the use of any supplements should be reviewed by a healthcare professional.


Q: Is it possible to develop a tolerance to Monolax over time?

A: Official regulatory documents indicate that prolonged use can lead to the bowels becoming dependent on the medication to function properly. The product is therefore only intended for short-term use.


Q: Can Monolax cause dry mouth?

A: Dry mouth is not listed as a common or primary side effect in official safety profiles. However, regulatory documents do note that severe adverse reactions such as dehydration, which is a risk with excessive or prolonged use, can cause symptoms like a dry, sticky mouth.


Q: What does the patient information leaflet say about stopping Monolax?

A: The official product information specifies a maximum time frame for use. Regulatory guidance indicates that if the medicine is needed for more than 1 week, use should be discontinued, and advice should be sought from a healthcare professional.


Q: Is Monolax safe for people who have kidney problems?

A: Official labeling advises caution in patients with fluid loss, particularly older adults, as they are vulnerable to harm from dehydration. The regulatory documents indicate that if a patient has renal insufficiency (kidney weakness), the use of Monolax should be reviewed by a physician.


Q: Are there any long-term effects of taking Monolax for many years?

A: Regulatory warnings state that prolonged or excessive use is associated with a serious safety concern: fluid and electrolyte imbalance (such as low potassium). The product is intended only for short-term relief.


Q: Is it true that Monolax is not recommended for people with heart issues?

A: The drug is not universally contraindicated for general heart issues. However, official labeling notes that if Monolax is taken with certain drugs like Diuretics or Adreno-corticosteroids, the risk of low potassium increases. Low potassium can then heighten sensitivity to certain heart medications called Cardiac Glycosides.


Q: Why are there different strengths or dosages of Monolax?

A: Different strengths and dosage forms (tablet vs. suppository) exist to accommodate different routes of administration and to achieve different onset times. For instance, the oral tablet is designed for a delayed, overnight effect, whereas the rectal suppository provides rapid relief.


Q: What does 'contraindication' mean in relation to Monolax?

A: A contraindication is an official term used in regulatory documents that describes a specific condition or circumstance where the use of Monolax is absolutely prohibited. For example, it is contraindicated if a patient has intestinal obstruction or acute inflammatory bowel disease.


Q: Has Monolax been approved by the FDA?

A: The active ingredient in Monolax, bisacodyl, is recognized and governed by the FDA as a substance in the category of Human OTC Drugs (Over-The-Counter). This classification covers its use for occasional constipation.


Q: What is the success rate described in the clinical trials for Monolax?

A: Clinical trials generally explore outcomes related to temporary relief compared to no treatment. However, official research documents focus on group patterns and provide a moderate certainty of evidence for outcomes like changes in the frequency of bowel movements, rather than quoting specific success percentages.


Q: Why is Monolax given to some patients and not others with the same problem?

A: Monolax is a stimulant laxative, which works differently from other types of laxatives. It is not suitable for everyone, as it is strictly contraindicated (prohibited) in patients with conditions like intestinal obstruction or severe dehydration. Its selection depends on the patient's specific symptoms and existing medical conditions.


Q: Does Monolax need to be taken with food?

A: Official guidance for the oral tablet confirms that it does not depend on being taken with or without regular food. However, the regulatory documents state that it should not be taken within one hour of consuming any dairy products or antacids.


Q: What is the difference between the active and inactive ingredients in Monolax?

A: The active ingredient (Bisacodyl) is the substance that produces the therapeutic effect. The inactive ingredients (sometimes called excipients) do not treat the condition but are necessary for the product's form, stability, and proper delivery, such as the enteric coating that protects the tablet.


Q: Does Monolax affect sleep patterns?

A: The oral tablet is specifically intended for administration at bedtime to produce an effect the following morning, leveraging the overnight period. Official safety warnings do not list sleep disturbances, such as insomnia, as a side effect of the medicine.

How should Monolax be stored and disposed of?

How to Store and Dispose of Monolax

The storage and disposal of Monolax (Bisacodyl) must follow official regulatory labeling to ensure product stability and safety.

Required Storage Conditions

Monolax must be stored at controlled room temperature, generally 25 C (77 F), with permitted excursions up to 30 C (86 F). The product must be kept in its original container, which should be tightly closed, and stored away from excess heat and moisture. It must be used before the labeled expiration date.

Child Safety and Disposal

As mandated by regulatory documents, Monolax must be kept out of the sight and reach of children.

Expired or unused medicine should not be discarded in household waste or wastewater. Disposal should follow governmental guidelines, such as using a drug take-back program or asking a pharmacist for proper disposal instructions, to protect the environment and prevent accidental access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Monolax found in:

A-Z Index: